Literature DB >> 17707103

Costs of an early intervention versus a conservative strategy in acute coronary syndrome.

David M Epstein1, Mark J Sculpher, Tim C Clayton, Rob A Henderson, Stuart J Pocock, Martin J Buxton, Keith A A Fox.   

Abstract

BACKGROUND: The Randomised Intervention Treatment of unstable Angina (RITA-3) found that non-ST-elevation myocardial infarction and unstable angina patients randomised to routine early arteriography experienced a lower rate of death or myocardial infarction than patients randomised to conservative therapy over a five year period of follow up. This paper uses data from the RITA-3 trial to compare the health service costs of the two strategies.
METHODS: The resource use data included initial arteriography and revascularisation procedures in the early intervention group and subsequently in both groups; in-patient days in hospital for any reason in the first year of follow-up; incidence of myocardial infarction; and cardiac medication.
RESULTS: After five years, the early intervention arm accrued a total mean cost of pound sterling 11,340 (euro 15,592) and the conservative arm a mean of pound sterling 9749(euro 13,405), an additional mean cost in the intervention arm of pound sterling 1591 (95% CI pound sterling 851 to pound sterling 2276) (euro 2188; 95%CI euro 1160 to euro 3228). On average, costs increased with age and were higher in male patients and in patients with severe angina. However, the incremental cost of the intervention strategy was consistent across different patient sub-groups.
CONCLUSION: Over a period of 5 years, the initial additional cost of a strategy of early intervention is only partially offset by subsequent interventions in patients managed conservatively.

Entities:  

Mesh:

Year:  2007        PMID: 17707103     DOI: 10.1016/j.ijcard.2007.06.008

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Expenditures of the German statutory health insurance system for patients suffering from acute coronary syndrome and treated with percutaneous coronary intervention.

Authors:  Heiko Friedel; Anne Delges; Johannes Clouth; Dana T Trautvetter
Journal:  Eur J Health Econ       Date:  2009-09-23

2.  How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.

Authors:  Laura Bojke; Andrea Manca; Miqdad Asaria; Ronan Mahon; Shijie Ren; Stephen Palmer
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

Review 3.  Patient-level costs of major cardiovascular conditions: a review of the international literature.

Authors:  Gina Nicholson; Shravanthi R Gandra; Ronald J Halbert; Akshara Richhariya; Robert J Nordyke
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

4.  The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application.

Authors:  Manuel A Espinoza; Andrea Manca; Karl Claxton; Mark J Sculpher
Journal:  Med Decis Making       Date:  2014-06-18       Impact factor: 2.583

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.